IAM’s fourth annual Pharma and Biotech IP will bring together leading in-house practitioners and expert counsel to discuss next-generation strategies for protecting and exploiting cutting-edge ...
the Big Pharma has acquired all commercial and intellectual property rights to Organovo’s FXR program. This includes lead candidate FXR314, an oral investigational med that the biotech was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback